Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 347 participants.
Also called NCT01113047
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 347 participants
- Sponsor
- Registry
-
NCT01113047
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01113047. Non-randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
- Acronym
- AWESOME
- Condition
- Essential Hypertension
- Intervention (Drug)
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01113047- Content hash
8f6fb6c66ae0b5dc6923e0cf374498274ab6234513c331025ed55d1b9cc5b44d